Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
- PMID: 26817954
- DOI: 10.1182/blood-2015-09-671172
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
Abstract
Recurrent somatic mutations of calreticulin (CALR) have been identified in patients harboring myeloproliferative neoplasms; however, their role in tumorigenesis remains elusive. Here, we found that the expression of mutant but not wild-type CALR induces the thrombopoietin (TPO)-independent growth of UT-7/TPO cells. We demonstrated that c-MPL, the TPO receptor, is required for this cytokine-independent growth of UT-7/TPO cells. Mutant CALR preferentially associates with c-MPL that is bound to Janus kinase 2 (JAK2) over the wild-type protein. Furthermore, we demonstrated that the mutant-specific carboxyl terminus portion of CALR interferes with the P-domain of CALR to allow the N-domain to interact with c-MPL, providing an explanation for the gain-of-function property of mutant CALR. We showed that mutant CALR induces the phosphorylation of JAK2 and its downstream signaling molecules in UT-7/TPO cells and that this induction was blocked by JAK2 inhibitor treatment. Finally, we demonstrated that c-MPL is required for TPO-independent megakaryopoiesis in induced pluripotent stem cell-derived hematopoietic stem cells harboring the CALR mutation. These findings imply that mutant CALR activates the JAK2 downstream pathway via its association with c-MPL. Considering these results, we propose that mutant CALR promotes myeloproliferative neoplasm development by activating c-MPL and its downstream pathway.
© 2016 by The American Society of Hematology.
Comment in
-
Mutant calreticulin: when a chaperone becomes intrusive.Blood. 2016 Mar 10;127(10):1219-21. doi: 10.1182/blood-2016-01-694182. Blood. 2016. PMID: 26965919
Similar articles
-
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.Blood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14. Blood. 2016. PMID: 26668133
-
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.Blood. 2018 Feb 15;131(7):782-786. doi: 10.1182/blood-2017-08-800896. Epub 2017 Dec 29. Blood. 2018. PMID: 29288169 Free PMC article.
-
Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.Cancer Sci. 2020 Aug;111(8):2682-2688. doi: 10.1111/cas.14503. Epub 2020 Jun 27. Cancer Sci. 2020. PMID: 32462673 Free PMC article. Review.
-
Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.Cancer Sci. 2017 Oct;108(10):1907-1912. doi: 10.1111/cas.13327. Epub 2017 Aug 8. Cancer Sci. 2017. PMID: 28741795 Free PMC article. Review.
-
Mutant calreticulin in myeloproliferative neoplasms.Blood. 2019 Dec 19;134(25):2242-2248. doi: 10.1182/blood.2019000622. Blood. 2019. PMID: 31562135 Free PMC article.
Cited by
-
When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.Rev Physiol Biochem Pharmacol. 2021;180:85-117. doi: 10.1007/112_2021_60. Rev Physiol Biochem Pharmacol. 2021. PMID: 34031738 Review.
-
ELC52: a novel megakaryocytic leukemia cell line with a CALR type 1 mutation.Leukemia. 2025 Jan;39(1):234-237. doi: 10.1038/s41375-024-02434-0. Epub 2024 Oct 8. Leukemia. 2025. PMID: 39379530 No abstract available.
-
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.Cancers (Basel). 2020 Jul 28;12(8):2100. doi: 10.3390/cancers12082100. Cancers (Basel). 2020. PMID: 32731609 Free PMC article. Review.
-
Recent insights regarding the molecular basis of myeloproliferative neoplasms.Korean J Intern Med. 2020 Jan;35(1):1-11. doi: 10.3904/kjim.2019.317. Epub 2019 Nov 29. Korean J Intern Med. 2020. PMID: 31778606 Free PMC article. Review.
-
Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.Leukemia. 2023 Apr;37(4):843-853. doi: 10.1038/s41375-023-01848-6. Epub 2023 Feb 22. Leukemia. 2023. PMID: 36813992 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous